Listed

CervoMed Inc.: Form 10-Q for the period ended Mar 31, 2015

Filed with the SEC on May 11, 2015 and accepted by EDGAR at May 11, 2015, 16:14 ET.

Share

Management's discussion and analysis

As filed, 29,520 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion of our financial condition and results of operations together with the unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this report and other financial information included in this report. The following discussion may contain predictions, estimates and other forward looking statements that involve a number of risks and uncertainties, including those discussed under “Part I — Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Special Note Regarding Forward Looking Statements” in this report and under “Part I — Item 1A. Risk Factors” in our annual report on Form10-K for the fiscal year ended December 31, 2014. These risks could cause our actual results to differ materially from any future performance suggested below.

Business Overview

We are a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology. Our lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. Our current pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. Our novel inhibition of the PI3K/Akt/mTOR pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which we are evaluating for the purpose of creating innovative therapies that are safe and effective treatments to satisfy unmet medical needs.

Our portfolio of product candidates is summarized in the following table:

Ophthalmology

The specific focus of our prescription ophthalmology business is on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway in the area of ophthalmology. Two human Phase I clinical studies with one of our palomids known as “RES-529” have been completed for wet age-related macular degeneration (“AMD”), both studies of which showed preliminary evidence of biologic activity and no serious toxicity. One of the two completed studies was sponsored by Paloma Pharmaceuticals, Inc., a company we acquired in March 2014, using intravitreal administration and was completed in December 2011. The second study was sponsored and conducted by The National Eye Institute using subconjunctival administration and was completed in July 2012. We currently are planning Phase I/II studies with RES-529 for wet age-related macular degeneration that we expect to begin in 2016 after we finalize CMC (chemistry, manufacturing and control) work for subconjunctival administration and complete necessary preclinical studies.

Oncology

Our novel PI3K/Akt/mTOR pathway inhibitor, RES-529, is in preclinical development for oncology. Through a series of in vitro and in vivo animal models, RES-529 has been shown to have activity in several cancer types due to its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway. RES-529 is a first-in-class inhibitor of both TORC1 and TORC2 that is mechanistically differentiated from other PI3K/Akt/mTOR pathway inhibitors currently in development. Signaling components of the PI3K/Akt/mTOR pathway are central regulators of cell proliferation, growth, differentiation, survival and angiogenesis. Up to 80 percent of tumor types have been shown to have an aberrant up-regulation of the PI3K pathway. Activation of this pathway has been observed in glioblastoma patients and is being pursued aggressively as a target for therapeutic intervention. We have shown activity in both in vitro and in vivo glioblastoma animal models and have demonstrated that RES-529 is orally bioavailable and can cross the blood brain barrier.

We believe glioblastoma represents substantial financial upside given the significant unmet medical need due to limited and modestly effective therapies. We plan to complete necessary work to start a Phase I/II glioblastoma human clinical trial in 2016. We also plan to initiate Phase II studies in other tumor types once the RES-529 maximum tolerated dose is determined in the initial portion of the glioblastoma study. We intend to focus in areas where preclinical evidence of activity has been demonstrated, specifically breast, prostate and/or lung cancers. In January 2015, the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation for RES-529 for the treatment of glioblastoma multiforme.

Dermatology

Our prescription dermatology business is based primarily upon a “soft” anti-androgen, known as “RES-440,” which is under development for the treatment of acne vulgaris. RES-440 has completed in vitro and in vivo proof-of-concept studies in tissue and animal models. We currently are working on CMC and necessary pre-clinical studies and are planning Phase I/Phase II studies in 2016 for the treatment of acne.

Other Indications/Products

We have rights to and own technologies and potential products beyond just those described above. It is our strategy to focus at the current time on ophthalmology, oncology and dermatology, specifically wet AMD, gliobastoma and acne, as described in this report. Beyond the potential products described in this report, we intend to continue to review our technologies and potential products on a regular basis and consider internal development in the future and the potential to out-license portions of our technology and potential products to other biopharmaceutical companies with greater focus and resources than ours or potentially in-license additional technologies and products for development.

In furtherance of this strategy, subsequent to the end of our first quarter of 2015, on April 30, 2015, we transferred certain of our non-focus technology rights to Or-Genix Therapeutics, Inc. (“Or-Genix”) in exchange for a 19.9% ownership interest in Or-Genix, representing 2,484,395 shares of the common stock of

Or-Genix, and we purchased $250,000 in perpetual non-redeemable preferred stock. The rights we transferred include exclusive rights to a compound currently known as “RES-102,” which is a “soft” estrogen potentially to be developed for the treatment of aging skin fragility/thinning and vulvo-vaginal atrophy, and exclusive rights to a compound currently known as “RES-214,” a non-prescription cosmeceutical product under development by a sublicensee. We previously licensed these rights from Yale University and as part of this transaction assigned those license agreements to Or-Genix. We also assigned our rights under a sublicense agreement with Ferndale Pharma Group, Inc. for the formulation, manufacture, sale and marketing of RES-214. Or-Genix is founded and owned primarily by Yael Schwartz, Ph.D., a former member of our Board of Directors and former Executive Vice President, Preclinical Development. The transfer of these technology rights to Or-Genix was executed since we are focusing our development efforts and resources on our other technologies.

Financial Summary

Our total working capital totaled $18,907,767, including $19,209,918 in cash and cash equivalents, as of March 31, 2015, compared to total working capital of $21,832,217, including $21,883,887 in cash and cash equivalents, as of December 31, 2014.

We recognized no revenues and our operating expenses were $3,518,936 during the first quarter of 2015. Our research and development expense increased 816% to $1,551,552 during the first quarter of 2015 compared to the first quarter of 2014 primarily as a result of our conducting research and development of our technologies and product candidates. Our general and administrative expenses increased 94% to $1,961,100 during the first quarter of 2015 compared to the first quarter of 2014 primarily as a result of employee and director non-cash stock-based compensation expenses.

We recognized a net loss of $(3,516,416) for the first quarter of 2015, or $(0.19) per share, compared to net loss of $(1,380,175), or $(0.23) per share, for the first quarter of 2014. We expect to continue to recognize net losses for the foreseeable future.

We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of our technologies and product candidates. We believe our cash and cash equivalents as of March 31, 2015 will be sufficient to fund our planned operations at least through December 31, 2015 and into the first half of 2016.

Results of Operations for Three Months Ended March 31, 2015 Compared to Three Months Ended March 31, 2014

The following table sets forth our results of operations for the three months ended March 31, 2015 and 2014.

Three Months Ended March 31, 2015 2014 $ Change % Change
Revenue $0 $0 $0 0%
Expenses
Research and development 1,551,552 169,332 1,382,220 816.2
General and administrative 1,961,100 1,010,858 950,242 94.0
Other (income) expenses (2,520) 8,655 (11,175) (129.1)
Net loss $(3,516,416) $(1,380,175) 2,136,241 154.8
Basic and diluted net loss per share $(0.19) $(0.23) $(0.04) (17.4)
Weighted average number of shares and equivalent shares outstanding 18,614,968 5,934,474 12,680,494 213.7

15

Revenues

We recognized no revenues during the three months ended March 31, 2015 or 2014.

Operating Expenses

Operating expenses were $3,518,936 during the three months ended March 31, 2015, representing an increase of 157%, compared to $1,371,520 during the three months ended March 31, 2014. This increase was primarily due to an increase in research and development expenses primarily as a result of our conducting research and development of our technologies and product candidates and an increase in general and administrative expenses primarily as a result of salary expense and employee and director non-cash stock-based compensation expenses.

We recognized $1,551,552 in research and development expenses during the three months ended March 31, 2015 compared to $169,332 in research and development expenses during the three months ended March 31, 2014. We expect that our research and development expenses will increase significantly in future periods compared to prior year periods due to our anticipated efforts to advance the research and development of our technologies and product candidates.

General and administrative expenses were $1,961,100 during the three months ended March 31, 2015, representing an increase of 94% from $1,010,858 during the three months ended March 31, 2014. This increase was primarily due to employee and director non-cash stock-based compensation expenses. We expect that our general and administrative expenses will increase in future periods compared to prior year periods as a result of increased personnel to support our product development efforts.

Stock-based compensation expense, which is included in research and development expenses and general and administrative expenses, was $605,427 during the three months ended March 31, 2015, representing an increase of 304%, over $149,885 during the three months ended March 31, 2014.

Depreciation and amortization was $6,284 during the three months ended March 31, 2015 compared to $191,330 during the three months ended March 31, 2014. This decrease was primarily related to a decrease in amortization expense attributable to intangible assets acquired in our acquisition of Canterbury Laboratories LLC and Hygeia Therapeutics, Inc. due to our abandonment and write-off of such intangible assets during the fourth quarter of 2014.

Other (Income) Expenses

Other income was $2,520 during the three months ended March 31, 2015 compared to other income of $49,639 during the three months ended March 31, 2014. Other income for the three months ended March 31, 2015 related primarily to the recognition of interest income. Other income for the three months ended March 31, 2014 related primarily to a $51,659 reduction in deferred taxes related to the amortization of the Canterbury intangible assets.

Interest Expense

Interest expense was zero during the three months ended March 31, 2015 compared to $58,294 during the three months ended March 31, 2014. Interest expense decreased due to a reduction in our total indebtedness during the last three quarterly periods of 2014 which eliminated all of our debt as of December 31, 2014.

Net Loss

We recognized a net loss of $(3,516,416) for the first quarter of 2015, or $(0.19) per share, compared to net loss of $(1,380,175), or $(0.23) per share, for the first quarter of 2014. We expect to incur net losses in future periods for the foreseeable future as we plan to continue our efforts to advance our technologies and product candidates.

Liquidity and Capital Resources

Working Capital

Our working capital totaled $18,907,767, including $19,209,918 in cash and cash equivalents, as of March 31, 2015, compared to working capital $21,832,217, including $21,883,887 in cash and cash equivalents, as of December 31, 2014.

The following table summarizes our working capital as of March 31, 2015 and December 31, 2014:

March 31, 2015 December 31, 2014
Cash and cash equivalents $19,209,918 $21,883,887
Prepaid expenses, deposits and other assets 1,790,783 2,286,930
Total current liabilities (2,092,934) (2,338,600)
Working capital $18,907,767 $21,832,217

We expect to continue to incur net losses for the foreseeable future. We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of our technologies and product candidates.

Cash Flows

The following table sets forth our cash flows for the three months ended March 31, 2015 and 2014:

Three Months Ended March 31, 2015 2014
Operating activities $(2,654,740) $(432,893)
Investing activities (19,229) —
Financing activities — 400,000
Net decrease in cash and cash equivalents $(2,673,969) $(32,893)

Operating Activities

Net cash used in operating activities, which consisted principally of cash expended on research and development and general and administrative activities, was $2,654,740, and $432,893 for the three months ended March 31, 2015 and 2014, respectively. The increase in cash used for operating activities is driven by the increase in our operating expenses as previously described.

Investing Activities

Purchase of fixed assets accounted for all $19,229 of cash used in investing activities for the three months ended March 31, 2015 compared to no cash used in or provided by investing activities during the three months ended March 31, 2014.

Financing Activities

Net cash provided by financing activities was $0 during the three months ended March 31, 2015 compared to $400,000 during the three months ended March 31, 2014. Net cash provided by financing activities during the prior year period resulted from proceeds on notes payable, which were converted into common shares and warrants to acquire common shares in the second quarter of 2014.

Capital Requirements

We expect to incur substantial expenses and generate significant operating losses as we continue to execute our business strategy, including:

  • synthesis and formulation of our product candidates;
  • conducting preclinical and clinical trials to pursue our product development initiatives;
  • hiring additional personnel for managerial, research and development, operations and other functions; and
  • implementing improved operational, financial and management systems.

To date, we have used primarily equity and debt financings to fund our ongoing business operations and short-term liquidity needs, and we expect to continue this practice for the foreseeable future. During 2014, we completed a private placement pursuant to which we raised approximately $35.6 million in gross proceeds and $31.9 million in net proceeds, after paying placement agent fees and commission and offering expenses. In the private placement, we issued an aggregate of 8,895,685 shares of our common stock and warrants to purchase an aggregate of 2,668,706 shares of common stock. The purchasers of common stock received warrants to purchase 0.3 shares of common stock for each share of common stock that investors purchased in the private placement. The purchase price of each common stock/warrant unit was $4.00. Each warrant is exercisable into one share of common stock at an initial exercise price of $4.80 per share.

We believe our cash and cash equivalents as of March 31, 2015 will be sufficient to fund our planned operations at least through December 31, 2015 and into the first half of 2016. However, we may require additional funds earlier. Accordingly, there is no assurance that we will not need or seek additional funding prior to such time. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable.

As of March 31, 2015, we did not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify or delay the development of our product candidates and our operations, or we may need to obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to obtain additional financing when needed, we may be forced to explore strategic alternatives, such as selling or merging our company or winding down our operations and liquidating our company.

To the extent that we raise additional capital through the sale of our common stock, the interests of our current stockholders may be diluted. If we issue preferred stock or convertible debt securities, it could affect the rights of our common stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock or convertible debt securities may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Contractual Obligations

Set forth below is information concerning our known contractual obligations as of March 31, 2015 that are fixed and determinable by year starting with the twelve months ending March 31, 2016.

Contractual Obligations Payments Due By Period Total Less than 1 Year 1-3 Years 3-5 Years More than 5 Years
Accrued board fees $59,688 $59,688 $— $— $—
Rent obligations 1,021,921 880,264 141,657 — —
Employee contracts 4,015,083 2,033,000 1,982,083 — —
Purchase obligations 1,103,970 1,099,710 4,260 — —
Total $6,200,662 $4,072,662 $2,128,000 $— $—

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.

Critical Accounting Policies

Certain of our critical accounting estimates require the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry and information available from other outside sources, as appropriate. Actual results may differ from these judgments under different assumptions or conditions. Different, reasonable estimates could have been used for the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial condition or results of operations. All of our critical accounting policies are more fully described in “Part II — Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies” set forth in our annual report on Form 10-K for the year ended December 31, 2014. There have been no changes to our critical accounting policies since December 31, 2014.

Special Note Regarding Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. In addition, we or others on our behalf may make forward-looking statements from time to time in oral presentations, including telephone conferences and/or web casts open to the public, in news releases or reports, on its Internet web site or otherwise. All statements other than statements of historical facts included in this report that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our plans, objectives, strategies and prospects regarding, among other things, our business, operating results and financial condition. We have identified some of these forward-looking statements with words like “believe,” “may,” “will,” “should,” “could,” “would,” “might,” “possible,” “potential,” “expect,” “intend,” “plan,” “predict,” “project,” “anticipate,” “estimate,” “approximate,” “continue,” other words and terms of similar meaning and the use of future dates. These forward-looking statements may be contained in this section, the notes to our financial statements and elsewhere in this report. Our forward-looking statements generally relate to:

  • the status and anticipated development of our product candidates;
  • the market size and anticipated market acceptance of our product candidates;
  • our future operating expenses, anticipated burn rate and whether and how long our existing cash and cash equivalents will be sufficient to fund our operations;
  • the effect of new accounting pronouncements and future health care, tax and other legislation; and
  • our anticipated substantial and continuing losses.

These forward-looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially from those matters expressed or implied by our forward-looking statements. Forward-looking statements (including oral representations) are only predictions or statements of current plans and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties, including, among other things, risks associated with:

  • our history of operating losses and negative cash flow;
  • our ability to generate revenues and obtain profitability;
  • our ability to obtain additional capital when needed or on acceptable terms and the effect of any future equity or debt financings on our stockholders;
  • our ability to successfully choose which of our product candidates should be developed and in which order;
  • the potential for changes in our focus on certain product candidates to other product candidates;
  • our success in developing new products and technologies, obtaining any required regulatory approvals for such products and technologies and obtaining market acceptance and commercial success with respect to such new products and technologies;
  • the timing of when, if ever, our product candidates will be approved and introduced commercially;
  • the size of the market and the level of market acceptance of our product candidates if and when they are commercialized;
  • our dependence on the successful development, regulatory approval and commercialization of our product candidates, which include primarily RES-529 and RES-440, which are in early stage development;
  • uncertainties regarding clinical drug development and the failure of our clinical trials to adequately demonstrate the safety and efficacy of our product candidates, which could prevent or delay regulatory approval and commercialization;
  • our dependence upon third-party clinical research organizations and other third parties to conduct and oversee our clinical trials and other aspects of product development;
  • our ability to acquire or invest in new businesses, products and technologies by way of a license, acquisition or merger transaction and the effect of such a transaction on our stockholders, business, operating results and financial condition;
  • our ability to comply with extensive laws, rules and regulations;
  • our ability to protect our proprietary technology and to operate our business without infringing the proprietary rights of third parties;
  • our ability to compete in a competitive industry;
  • our dependence upon key employees;
  • our prior and any future acquisitions, including difficulties in integrating the acquired businesses and their respective personnel and products; difficulties or delays in realizing the anticipated benefits of our prior acquisitions or any additional acquired companies and their product candidates; challenges due to limited or no direct prior experience in new markets we may enter; the potential loss of key employees; inability to successfully develop new products and services on a timely basis that address our new market opportunities post-acquisition; unanticipated costs, litigation and other contingent liabilities; incurrence of acquisition and integration related costs, accounting charges, or amortization costs for acquired intangible assets; potential write-down of goodwill, acquired intangible assets and/or deferred tax assets; and additional legal, financial and accounting challenges and complexities in areas such as intellectual property, tax planning, cash management and financial reporting;
  • our ability to maintain effective internal control over financial reporting;
  • changes in applicable laws or regulations and our failure to comply with applicable laws, rules and regulations;
  • changes in generally accepted accounting principles and the effect of new accounting pronouncements;
  • conditions and changes in the biopharmaceutical industry or in general economic or business conditions;
  • our ability to obtain and maintain a national securities exchange listing for our common stock and the ability of our stockholders to buy or sell our common stock in light of the low trading volume and liquidity of our common stock; and
  • pending and future litigation, which could have an adverse effect on our business, financial condition or operating results.

For more information regarding these and other uncertainties and factors that could cause our actual results to differ materially from what we have anticipated in our forward-looking statements or otherwise could materially adversely affect our business, financial condition or operating results, see “Part I — Item 1A. Risk Factors” of our annual report on Form 10-K for the fiscal year ended December 31, 2014. The risks and uncertainties described above and in “Part I — Item 1A. Risk Factors” of our annual report on Form 10-K for the fiscal year ended December 31, 2014 are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. We assume no obligation to update, amend or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our future annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K we file with or furnish to the Securities and Exchange Commission.

Controls and procedures

As filed, 4,334 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures” means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

We maintain disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible internal controls. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.

Our principal executive officer and principal financial officer do not expect that our disclosure controls and procedures or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Change in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2015 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2015-01-01 to 2015-03-31$1.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-01-01 to 2015-03-31−$3.5mus-gaap:OperatingIncomeLoss
Diluted EPS3 months2015-01-01 to 2015-03-31−$0.19us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2015-01-01 to 2015-03-3118,614,968 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2015-01-01 to 2015-03-31−$2.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2015-01-01 to 2015-03-31$19.2kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-03-31$19.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-03-31$21.0mus-gaap:AssetsCurrent
Total assetsAt period end2015-03-31$39.6mus-gaap:Assets
Current liabilitiesAt period end2015-03-31$2.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-03-31$4.4mus-gaap:Liabilities
Shareholders' equityAt period end2015-03-31$35.3mus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0001104659-15-036824. Last ingested by Listed: Nov 10, 2026, 02:07 ET. Listed shows no prices and gives no investment advice.